🎉 M&A multiples are live!
Check it out!

Annovis Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Annovis Bio and similar public comparables like Vivoryon Therapeutics, Galapagos, and Benevolent AI.

Annovis Bio Overview

About Annovis Bio

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.


Founded

2008

HQ

United States of America
Employees

8

Website

annovisbio.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$13.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Annovis Bio Financials

Annovis Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Annovis Bio achieved revenue of n/a and an EBITDA of -$26.7M.

Annovis Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Annovis Bio valuation multiples based on analyst estimates

Annovis Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$45.0M -$26.7M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$25.3M -$56.2M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Annovis Bio Stock Performance

As of April 15, 2025, Annovis Bio's stock price is $1.

Annovis Bio has current market cap of $24.2M, and EV of $13.6M.

See Annovis Bio trading valuation data

Annovis Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$13.6M $24.2M XXX XXX XXX XXX $-2.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Annovis Bio Valuation Multiples

As of April 15, 2025, Annovis Bio has market cap of $24.2M and EV of $13.6M.

Annovis Bio's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Annovis Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Annovis Bio and 10K+ public comps

Annovis Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $13.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.5x XXX XXX XXX
P/E -1.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Annovis Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Annovis Bio Valuation Multiples

Annovis Bio's NTM/LTM revenue growth is n/a

Annovis Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.3M for the same period.

Over next 12 months, Annovis Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Annovis Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Annovis Bio and other 10K+ public comps

Annovis Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -41% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $3.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Annovis Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Annovis Bio M&A and Investment Activity

Annovis Bio acquired  XXX companies to date.

Last acquisition by Annovis Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Annovis Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Annovis Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Annovis Bio

When was Annovis Bio founded? Annovis Bio was founded in 2008.
Where is Annovis Bio headquartered? Annovis Bio is headquartered in United States of America.
How many employees does Annovis Bio have? As of today, Annovis Bio has 8 employees.
Who is the CEO of Annovis Bio? Annovis Bio's CEO is Dr. Maria Maccecchini, PhD.
Is Annovis Bio publicy listed? Yes, Annovis Bio is a public company listed on NYS.
What is the stock symbol of Annovis Bio? Annovis Bio trades under ANVS ticker.
When did Annovis Bio go public? Annovis Bio went public in 2020.
Who are competitors of Annovis Bio? Similar companies to Annovis Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Annovis Bio? Annovis Bio's current market cap is $24.2M
Is Annovis Bio profitable? Yes, Annovis Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.